Evaluation of Quality of Life and Survival With MS-20 in Patient With Advanced Hepatocellular Carcinoma (FDA IND 74572)
To evaluate Quality of Life (QoL) score of MS-20 versus placebo in advanced HCC patients using European Organization for Research and Treatment of Cancer (EORTC) QLQ C-30 questionnaire.
Hepatocellular Carcinoma
DRUG: MS-20|DRUG: Placebo
To evaluate Quality of Life (QoL) score of MS-20 versus placebo in advanced HCC patients, 24 weeks
Overall survival, Overall survival rate, Change from baseline of the highest weight observed, Change from baseline of body weight, 24 weeks
To evaluate Quality of Life (QoL) score of MS-20 versus placebo in advanced HCC patients using European Organization for Research and Treatment of Cancer (EORTC) QLQ C-30 questionnaire.